Kyprolis
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. The proteasome is a cellular complex that breaks down proteins; it is believed to play a critical role in the degradation (and therefore regulation) of a number of proteins involved in the regulation of cell cycle, apoptosis, and angiogenesis. In vitro, Kyprolis has shown antiproliferative and proapoptotic activity in both solid and hematologic tumor cells. In animal studies, it was shown to inhibit proteasome activity and delay tumor growth in models of multiple myeloma, hematological malignancies, and solid tumors.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Kyprolis : Multiple myeloma
30 Kyprolis : NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
18 Figure 1: Kyprolis for multiple myeloma – SWOT analysis
19 Figure 2: Datamonitor Healthcare’s drug assessment summary of Kyprolis for multiple myeloma
20 Figure 3: Datamonitor Healthcare’s drug assessment summary of Kyprolis for multiple myeloma
23 Figure 4: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
33 Figure 5: Kyprolis for mantle cell lymphoma – SWOT analysis
LIST OF TABLES
6 Table 1: Kyprolis drug profile
8 Table 2: Kyprolis pivotal trial data in multiple myeloma
11 Table 3: Kyprolis late-phase trial data in multiple myeloma
15 Table 4: Kyprolis early-phase trial data in multiple myeloma
17 Table 5: Kyprolis ongoing Phase III trials in multiple myeloma
24 Table 6: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
26 Table 7: Patients treated with Kyprolis across the US, Japan, and five major EU markets, by country, 2017–26
31 Table 8: Kyprolis drug profile
32 Table 9: Kyprolis Phase I/II trials in mantle cell lymphoma
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Digital Pharma: Are We Nearly There? 
Sign up to the